Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy

Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy

Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurpibul L., Puthanakit T., Sirisanthana T., Sirisanthana V.
Format: Article
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-77951814475&partnerID=40&md5=2f0ea52adec1111a9724c5f9c093fa12
http://www.ncbi.nlm.nih.gov/pubmed/20377409
http://cmuir.cmu.ac.th/handle/6653943832/2581
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-2581
record_format dspace
spelling th-cmuir.6653943832-25812014-08-30T02:25:06Z Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy Aurpibul L. Puthanakit T. Sirisanthana T. Sirisanthana V. Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination. © 2010 by the Infectious Diseases Society of America. All rights reserved. 2014-08-30T02:25:06Z 2014-08-30T02:25:06Z 2010 Article 10584838 10.1086/652150 20377409 CIDIE http://www.scopus.com/inward/record.url?eid=2-s2.0-77951814475&partnerID=40&md5=2f0ea52adec1111a9724c5f9c093fa12 http://www.ncbi.nlm.nih.gov/pubmed/20377409 http://cmuir.cmu.ac.th/handle/6653943832/2581 English
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination. © 2010 by the Infectious Diseases Society of America. All rights reserved.
format Article
author Aurpibul L.
Puthanakit T.
Sirisanthana T.
Sirisanthana V.
spellingShingle Aurpibul L.
Puthanakit T.
Sirisanthana T.
Sirisanthana V.
Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy
author_facet Aurpibul L.
Puthanakit T.
Sirisanthana T.
Sirisanthana V.
author_sort Aurpibul L.
title Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy
title_short Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy
title_full Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy
title_fullStr Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy
title_full_unstemmed Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy
title_sort persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in hiv-infected children receiving antiretroviral therapy
publishDate 2014
url http://www.scopus.com/inward/record.url?eid=2-s2.0-77951814475&partnerID=40&md5=2f0ea52adec1111a9724c5f9c093fa12
http://www.ncbi.nlm.nih.gov/pubmed/20377409
http://cmuir.cmu.ac.th/handle/6653943832/2581
_version_ 1681419885716963328

Similar Items